Terms: = Prostate cancer AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR
314 results:
1. Diagnostic accuracy of qualitative and quantitative magnetic resonance imaging-guided contrast-enhanced ultrasound (MRI-guided CEUS) for the detection of prostate cancer: a prospective and multicenter study.
Liu Y; Lu D; Xu G; Wang S; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
Radiol Med; 2024 Apr; 129(4):585-597. PubMed ID: 38512615
[TBL] [Abstract] [Full Text] [Related]
2. Epidemiology of and Risk Factors in Postoperative Complications from Robotically Assisted Laparoscopic Radical prostatectomy in Contemporary National Surgical Quality Improvement Program Data.
Homer A; Golijanin B; Schmitt P; Bhatt V; Pareek G; Hyams ES
J Endourol; 2024 Mar; 38(3):270-275. PubMed ID: 38251639
[No Abstract] [Full Text] [Related]
3. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
4. Multimorbidity clusters in adults 50 years or older with and without a history of cancer: National Health Interview Survey, 2018.
Plasencia G; Gray SC; Hall IJ; Smith JL
BMC Geriatr; 2024 Jan; 24(1):50. PubMed ID: 38212690
[TBL] [Abstract] [Full Text] [Related]
5. Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
Filipas DK; Labban M; Beatrici E; Stone BV; Qian Z; D Andrea V; Ludwig TA; Reis LO; Cole AP; Trinh QD
Vaccine; 2024 Jan; 42(3):441-447. PubMed ID: 38184391
[TBL] [Abstract] [Full Text] [Related]
6. The levels and trends of cancer incidence in the elderly population at national and sub-national scales in Iran from 1990 to 2016.
Shokri Varniab Z; Saeedi Moghaddam S; Pourabhari Langroudi A; Azadnajafabad S; Mortazavi SS; Sheidaei A; Gohari K; Farzi Y; Shirzad Moghaddam Z; Sohrabi H; Shati M
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1937. PubMed ID: 38049962
[TBL] [Abstract] [Full Text] [Related]
7. Differences in overall survival of penile cancer patients versus population-based controls.
Scheipner L; Tappero S; Piccinelli ML; Barletta F; Garcia CC; Incesu RB; Morra S; Tian Z; Saad F; Shariat SF; Terrone C; De Cobelli O; Briganti A; Chun FKH; Tilki D; Longo N; Seles M; Ahyai S; Karakiewicz PI
Int J Urol; 2024 Mar; 31(3):274-279. PubMed ID: 38014575
[TBL] [Abstract] [Full Text] [Related]
8. Global viewpoints: updates on prostate cancer in Sub-Saharan Africa.
Jalloh M; Cassell A; Niang L; Rebbeck T
BJU Int; 2024 Jan; 133(1):6-13. PubMed ID: 37702258
[TBL] [Abstract] [Full Text] [Related]
9. Acceptability of a shared cancer follow-up model of care between general practitioners and radiation oncologists: A qualitative evaluation.
Sandell T; Schütze H; Miller A
Health Expect; 2023 Dec; 26(6):2441-2452. PubMed ID: 37583292
[TBL] [Abstract] [Full Text] [Related]
10. Assessing the Feasibility of Using Artificial Intelligence-Segmented Dominant Intraprostatic Lesion for Focal Intraprostatic Boost With External Beam Radiation Therapy.
Tsui JMG; Kehayias CE; Leeman JE; Nguyen PL; Peng L; Yang DD; Moningi S; Martin N; Orio PF; D'Amico AV; Bredfeldt JS; Lee LK; Guthier CV; King MT
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):74-84. PubMed ID: 37517600
[TBL] [Abstract] [Full Text] [Related]
11. An uncertainty-incorporated method for fast beam angle selection in intensity-modulated proton therapy.
Ramar N; Meher SR
J Cancer Res Ther; 2023; 19(3):688-696. PubMed ID: 37470595
[TBL] [Abstract] [Full Text] [Related]
12. The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic prostate cancer.
Joyce DD; Qin X; Sharma V; Boorjian SA; Barocas DA; Dusetzina SB; Moses KA
J Urol; 2023 Sep; 210(3):447-453. PubMed ID: 37341420
[TBL] [Abstract] [Full Text] [Related]
13. A Narrative Synthesis of Literature on the Barriers to Timely Diagnosis and Treatment of cancer in Sub-Saharan Africa.
Mwamba M; Lombe DC; Msadabwe S; Bond V; Simwinga M; Sentoogo Ssemata A; Muhumuza R; Seeley J; Mwaka AD; Aggarwal A
Clin Oncol (R Coll Radiol); 2023 Sep; 35(9):e537-e548. PubMed ID: 37302880
[TBL] [Abstract] [Full Text] [Related]
14. Analysis of cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and Opportunities.
Davies L; Milner DA; Shulman LN; Kyokunda L; Bedada A; Vuylsteke P; Masalu N; Jackson P; Jennings N; Odunlami A; Mtshali P; Dugan U
JCO Glob Oncol; 2023 Jun; 9():e2200203. PubMed ID: 37290022
[TBL] [Abstract] [Full Text] [Related]
15. Comparing Risk for Second Primary cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for prostate cancer, 2002-2015.
Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
[TBL] [Abstract] [Full Text] [Related]
16. Benchmarking the Radiation Oncology Alternative Payment Model: Changes in Medicare Reimbursement for 16 Common Radiation Therapy Treatment Courses.
Hogan JS; Karraker P; Fischer-Valuck BW; Vapiwala N; Mehta MP; Perez CA; Baumann JC; Bradley JD; Baumann BC
Pract Radiat Oncol; 2023; 13(5):e389-e394. PubMed ID: 37172757
[TBL] [Abstract] [Full Text] [Related]
17. Effect of type of definitive treatment on race-based differences in prostate cancer-specific survival.
Frego N; Labban M; Stone BV; Koelker M; Alkhatib K; Lughezzani G; Buffi NM; Lipsitz SR; Weissman JS; Fletcher SA; Kibel AS; Trinh QD; Cole AP
Prostate; 2023 Aug; 83(11):1099-1111. PubMed ID: 37150867
[TBL] [Abstract] [Full Text] [Related]
18. Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer.
Roy S; Wallis CJD; Morgan SC; Kishan AU; Le ATT; Malone J; Sun Y; Spratt DE; Saad F; Malone S
Prostate; 2023 Jul; 83(10):912-921. PubMed ID: 37071764
[TBL] [Abstract] [Full Text] [Related]
19. Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk.
Dite GS; Spaeth E; Murphy NM; Allman R
Prostate; 2023 Jul; 83(10):962-969. PubMed ID: 37062910
[TBL] [Abstract] [Full Text] [Related]
20. Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI.
Ma Z; Wang X; Zhang W; Gao K; Wang L; Qian L; Mu J; Zheng Z; Cao X
World J Surg Oncol; 2023 Mar; 21(1):83. PubMed ID: 36882854
[TBL] [Abstract] [Full Text] [Related]
[Next]
